The DOI matches its Crossref record; 115 of the 115 references it cites were found in a registry or an index.
Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances
Open accessAbstract
Bruton’s tyrosine kinase (BTK) inhibitor is a promising novel agent that has potential efficiency in B-cell malignancies. It took approximately 20 years from target discovery to new drug approval. The first-in-class drug ibrutinib creates possibilities for an era of chemotherapy-free management of B-cell malignancies, and it is so popular that gross sales have rapidly grown to more than 230 billion dollars in just 6 years, with annual sales exceeding 80 billion dollars; it also became one of the five top-selling medicines in the world. Numerous clinical trials of BTK inhibitors in cancers were initiated in the last decade, and ~73 trials were intensively announced or updated with extended follow-up data in the most recent 3 years. In this review, we summarized the significant milestones in the preclinical discovery and clinical development of BTK inhibitors to better understand the clinical and commercial potential as well as the directions being taken. Furthermore, it also contributes impactful lessons regarding the discovery and development of other novel therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21590 · Cited by 20,444
Clinical development success rates for investigational drugs
Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., & Rosenthal, J. (2014) · Nature Biotechnology · doi:10.1038/nbt.2786 · Cited by 2,536
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
Byrd, J. C., Furman, R. R., Coutre, S. E., Flinn, I. W., Burger, J. A., Blum, K. A., Grant, B., Sharman, J. P., Coleman, M., Wierda, W. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215637 · Cited by 2,270
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma
Wang, M. L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B. S., Jurczak, W., Advani, R. H., Romaguera, J. E., Williams, M. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306220 · Cited by 1,685
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
Burger, J. A., Tedeschi, A., Barr, P. M., Robak, T., Owen, C., Ghia, P., Bairey, O., Hillmen, P., Bartlett, N. L., Li, J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509388 · Cited by 1,583
Honigberg, L. A., Smith, A. M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S., Pan, Z., Thamm, D. H., Miller, R. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004594107 · Cited by 1,561
Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
Goede, V., Fischer, K., Busch, R., Engelke, A., Eichhorst, B., Wendtner, C. M., Chagorova, T., de la Serna, J., Dilhuydy, M.-S., Illmer, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1313984 · Cited by 1,518
Vetrie, D., Vořechovský, I., Sideras, P., Holland, J., Davies, A., Flinter, F., Hammarström, L., Kinnon, C., Levinsky, R., Bobrow, M., et al. (1993) · Nature · doi:10.1038/361226a0 · Cited by 1,461
Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
Woyach, J. A., Furman, R. R., Liu, T.-M., Ozer, H. G., Zapatka, M., Ruppert, A. S., Xue, L., Li, D. H.-H., Steggerda, S. M., Versele, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400029 · Cited by 1,275 · cited 1×
“SH2 (BTK Thr316) domains of BTK have been discovered [110].”
BackgroundFry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1427.3.11 · Cited by 1,236 · cited 1×
“MCL is characterized by cell-cycle dysregulation, and the CDK4 inhibitor palbociclib can prolong early G1 cell arrest in MCL tumour cells [37].”
BackgroundAdvani, R. H., Buggy, J. J., Sharman, J. P., Smith, S. M., Boyd, T. E., Grant, B., Kolibaba, K. S., Furman, R. R., Rodriguez, S., Chang, B. Y., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.7906 · Cited by 1,128 · cited 4×
“The PCYC-1103 study established 420 mg as the RP2D, and the randomized phase III RESONATE trial (PCYC-1112) proved that ibrutinib is superior to anti-CD20 ofatumumab, even in patients with unfavourable risks, such as del 17p, del 11q, and unmutated IGVH [53–55].”
BackgroundInfluential2016 US lymphoid malignancy statistics by World Health Organization subtypes
Teras, L. R., DeSantis, C. E., Cerhan, J. R., Morton, L. M., Jemal, A., & Flowers, C. R. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21357 · Cited by 1,125 · cited 1×
“Approximately 93% of NHLs are derived from B cells, and B-cell malignancies comprise the most common haematologic malignancy with an estimated 98,280 new cases and 24,000 deaths in the US in 2020 [1, 2].”
BackgroundTargeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
Wilson, W. H., Young, R. M., Schmitz, R., Yang, Y., Pittaluga, S., Wright, G., Lih, C.-J., Williams, P. M., Shaffer, A. L., Gerecitano, J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3884 · Cited by 1,113
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
Woyach, J. A., Ruppert, A. S., Heerema, N. A., Zhao, W., Booth, A. M., Ding, W., Bartlett, N. L., Brander, D. M., Barr, P. M., Rogers, K. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1812836 · Cited by 962
Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia
Treon, S. P., Tripsas, C. K., Meid, K., Warren, D., Varma, G., Green, R., Argyropoulos, K. V., Yang, G., Cao, Y., Xu, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501548 · Cited by 942
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
Byrd, J. C., Harrington, B., O’Brien, S., Jones, J. A., Schuh, A., Devereux, S., Chaves, J., Wierda, W. G., Awan, F. T., Brown, J. R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509981 · Cited by 897
Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
Shanafelt, T. D., Wang, X. V., Kay, N. E., Hanson, C. A., O’Brien, S., Barrientos, J., Jelinek, D. F., Braggio, E., Leis, J. F., Zhang, C. C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817073 · Cited by 749
Davids, M. S., Roberts, A. W., Seymour, J. F., Pagel, J. M., Kahl, B. S., Wierda, W. G., Puvvada, S., Kipps, T. J., Anderson, M. A., Salem, A. H., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.4320 · Cited by 748
Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase
Pan, Z., Scheerens, H., Li, S., Schultz, B. E., Sprengeler, P. A., Burrill, L. C., Mendonca, R. V., Sweeney, M. D., Scott, K. C. K., Grothaus, P. G., et al. (2007) · ChemMedChem · doi:10.1002/cmdc.200600221 · Cited by 674
Flinn, I. W., van der Jagt, R., Kahl, B. S., Wood, P., Hawkins, T. E., MacDonald, D., Hertzberg, M., Kwan, Y.-L., Simpson, D., Craig, M., et al. (2014) · Blood · doi:10.1182/blood-2013-11-531327 · Cited by 643
Sharman, J. P., Egyed, M., Jurczak, W., Skarbnik, A., Pagel, J. M., Flinn, I. W., Kamdar, M., Munir, T., Walewska, R., Corbett, G., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30262-2 · Cited by 631
Younes, A., Sehn, L. H., Johnson, P., Zinzani, P. L., Hong, X., Zhu, J., Patti, C., Belada, D., Samoilova, O., Suh, C., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02403 · Cited by 608
Moreno, C., Greil, R., Demirkan, F., Tedeschi, A., Anz, B., Larratt, L., Simkovic, M., Samoilova, O., Novak, J., Ben-Yehuda, D., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30788-5 · Cited by 556
Targeting Bruton's tyrosine kinase in B cell malignancies
Hendriks, R. W., Yuvaraj, S., & Kil, L. P. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3702 · Cited by 552
Hunter, Z. R., Xu, L., Yang, G., Zhou, Y., Liu, X., Cao, Y., Manning, R. J., Tripsas, C., Patterson, C. J., Sheehy, P., et al. (2014) · Blood · doi:10.1182/blood-2013-09-525808 · Cited by 488
Munir, T., Brown, J. R., O'Brien, S., Barrientos, J. C., Barr, P. M., Reddy, N. M., Coutre, S., Tam, C. S., Mulligan, S. P., Jaeger, U., et al. (2019) · American Journal of Hematology · doi:10.1002/ajh.25638 · Cited by 473
Burger, J. A., Barr, P. M., Robak, T., Owen, C., Ghia, P., Tedeschi, A., Bairey, O., Hillmen, P., Coutre, S. E., Devereux, S., et al. (2020) · Leukemia · doi:10.1038/s41375-019-0602-x · Cited by 467
O'Brien, S., Furman, R. R., Coutre, S. E., Sharman, J. P., Burger, J. A., Blum, K. A., Grant, B., Richards, D. A., Coleman, M., Wierda, W. G., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70513-8 · Cited by 466
Tam, C. S., Opat, S., D'Sa, S., Jurczak, W., Lee, H.-P., Cull, G., Owen, R. G., Marlton, P., Wahlin, B. E., Sanz, R. G., et al. (2020) · Blood · doi:10.1182/blood.2020006844 · Cited by 466
Dreyling, M., Jurczak, W., Jerkeman, M., Silva, R. S., Rusconi, C., Trneny, M., Offner, F., Caballero, D., Joao, C., Witzens-Harig, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00667-4 · Cited by 463
Wang, M., Rule, S., Zinzani, P. L., Goy, A., Casasnovas, O., Smith, S. D., Damaj, G., Doorduijn, J., Lamy, T., Morschhauser, F., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33108-2 · Cited by 453 · cited 1×
“By contrast, single-agent acalabrutinib demonstrated an ORR/CR of 81%/42%, and the FDA has accelerated approved it to treat R/R MCL based on this phase 2 trial in 2017 [31].”
BackgroundSagiv-Barfi, I., Kohrt, H. E. K., Czerwinski, D. K., Ng, P. P., Chang, B. Y., & Levy, R. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1500712112 · Cited by 444
Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma
Tam, C. S., Anderson, M. A., Pott, C., Agarwal, R., Handunnetti, S., Hicks, R. J., Burbury, K., Turner, G., Di Iulio, J., Bressel, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1715519 · Cited by 433
Targeting B cell receptor signalling in cancer: preclinical and clinical advances
Burger, J. A., & Wiestner, A. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.121 · Cited by 431
Chanan-Khan, A., Cramer, P., Demirkan, F., Fraser, G., Silva, R. S., Grosicki, S., Pristupa, A., Janssens, A., Mayer, J., Bartlett, N. L., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00465-9 · Cited by 415
Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma
Grommes, C., Pastore, A., Palaskas, N., Tang, S. S., Campos, C., Schartz, D., Codega, P., Nichol, D., Clark, O., Hsieh, W.-Y., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0613 · Cited by 409
O’Brien, S., Furman, R. R., Coutre, S., Flinn, I. W., Burger, J. A., Blum, K., Sharman, J., Wierda, W., Jones, J., Zhao, W., et al. (2018) · Blood · doi:10.1182/blood-2017-10-810044 · Cited by 385
Barf, T., Covey, T., Izumi, R., van de Kar, B., Gulrajani, M., van Lith, B., van Hoek, M., de Zwart, E., Mittag, D., Demont, D., et al. (2017) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.242909 · Cited by 380
Farooqui, M. Z. H., Valdez, J., Martyr, S., Aue, G., Saba, N., Niemann, C. U., Herman, S. E. M., Tian, X., Marti, G., Soto, S., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71182-9 · Cited by 372
Ghia, P., Pluta, A., Wach, M., Lysak, D., Kozak, T., Simkovic, M., Kaplan, P., Kraychok, I., Illes, A., de la Serna, J., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03355 · Cited by 372
Tam, C. S., Trotman, J., Opat, S., Burger, J. A., Cull, G., Gottlieb, D., Harrup, R., Johnston, P. B., Marlton, P., Munoz, J., et al. (2019) · Blood · doi:10.1182/blood.2019001160 · Cited by 361
Guo, Y., Liu, Y., Hu, N., Yu, D., Zhou, C., Shi, G., Zhang, B., Wei, M., Liu, J., Luo, L., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00687 · Cited by 359
Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s Macroglobulinemia
Dimopoulos, M. A., Tedeschi, A., Trotman, J., García-Sanz, R., Macdonald, D., Leblond, V., Mahe, B., Herbaux, C., Tam, C., Orsucci, L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802917 · Cited by 357
Yang, G., Zhou, Y., Liu, X., Xu, L., Cao, Y., Manning, R. J., Patterson, C. J., Buhrlage, S. J., Gray, N., Tai, Y.-T., et al. (2013) · Blood · doi:10.1182/blood-2012-12-475111 · Cited by 352
Goy, A., Sinha, R., Williams, M. E., Kalayoglu Besisik, S., Drach, J., Ramchandren, R., Zhang, L., Cicero, S., Fu, T., & Witzig, T. E. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.2835 · Cited by 349
Lynch, T. J., Kim, E. S., Eaby, B., Garey, J., West, D. P., & Lacouture, M. E. (2007) · The Oncologist · doi:10.1634/theoncologist.12-5-610 · Cited by 341
O'Brien, S., Jones, J. A., Coutre, S. E., Mato, A. R., Hillmen, P., Tam, C., Österborg, A., Siddiqi, T., Thirman, M. J., Furman, R. R., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30212-1 · Cited by 340
Integration of B cell responses through Toll-like receptors and antigen receptors
Rawlings, D. J., Schwartz, M. A., Jackson, S. W., & Meyer-Bahlburg, A. (2012) · Nature Reviews Immunology · doi:10.1038/nri3190 · Cited by 339
Soussain, C., Choquet, S., Blonski, M., Leclercq, D., Houillier, C., Rezai, K., Bijou, F., Houot, R., Boyle, E., Gressin, R., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.05.024 · Cited by 305
Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma
Noy, A., de Vos, S., Thieblemont, C., Martin, P., Flowers, C. R., Morschhauser, F., Collins, G. P., Ma, S., Coleman, M., Peles, S., et al. (2017) · Blood · doi:10.1182/blood-2016-10-747345 · Cited by 298
Wang, M., Fayad, L., Wagner-Bartak, N., Zhang, L., Hagemeister, F., Neelapu, S. S., Samaniego, F., McLaughlin, P., Fanale, M., Younes, A., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70200-0 · Cited by 297
Woyach, J. A., Smucker, K., Smith, L. L., Lozanski, A., Zhong, Y., Ruppert, A. S., Lucas, D., Williams, K., Zhao, W., Rassenti, L., et al. (2014) · Blood · doi:10.1182/blood-2013-09-527853 · Cited by 280 · cited 1×
“Although 20% of patients had a partial remission with lymphocytosis, generally in the first weeks of treatment, it is believed that this was due to the redistribution of CLL cells from solid lymphoma manifestations into the bloodstream and should not be confused for disease progression [67].”
BackgroundChiron, D., Di Liberto, M., Martin, P., Huang, X., Sharman, J., Blecua, P., Mathew, S., Vijay, P., Eng, K., Ali, S., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0098 · Cited by 273
Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study
Hillmen, P., Rawstron, A. C., Brock, K., Muñoz-Vicente, S., Yates, F. J., Bishop, R., Boucher, R., MacDonald, D., Fegan, C., McCaig, A., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00894 · Cited by 272
Fowler, N. H., Davis, R. E., Rawal, S., Nastoupil, L., Hagemeister, F. B., McLaughlin, P., Kwak, L. W., Romaguera, J. E., Fanale, M. A., Fayad, L. E., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70455-3 · Cited by 264
Cheah, C. Y., Seymour, J. F., & Wang, M. L. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.5904 · Cited by 264
Younes, A., Thieblemont, C., Morschhauser, F., Flinn, I., Friedberg, J. W., Amorim, S., Hivert, B., Westin, J., Vermeulen, J., Bandyopadhyay, N., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70311-0 · Cited by 254
Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor
Wu, J., Zhang, M., & Liu, D. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0250-9 · Cited by 254
Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab
Byrd, J. C., Hillmen, P., O’Brien, S., Barrientos, J. C., Reddy, N. M., Coutre, S., Tam, C. S., Mulligan, S. P., Jaeger, U., Barr, P. M., et al. (2019) · Blood · doi:10.1182/blood-2018-08-870238 · Cited by 245
Zhang, L., Yao, Y., Zhang, S., Liu, Y., Guo, H., Ahmed, M., Bell, T., Zhang, H., Han, G., Lorence, E., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aau1167 · Cited by 233
Ibrutinib antagonizes rituximab-dependent NK cell–mediated cytotoxicity
Kohrt, H. E., Sagiv-Barfi, I., Rafiq, S., Herman, S. E. M., Butchar, J. P., Cheney, C., Zhang, X., Buggy, J. J., Muthusamy, N., Levy, R., et al. (2014) · Blood · doi:10.1182/blood-2014-01-547869 · Cited by 217
Wang, M. L., Lee, H., Chuang, H., Wagner-Bartak, N., Hagemeister, F., Westin, J., Fayad, L., Samaniego, F., Turturro, F., Oki, Y., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00438-6 · Cited by 216
Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study
Ahn, I. E., Farooqui, M. Z. H., Tian, X., Valdez, J., Sun, C., Soto, S., Lotter, J., Housel, S., Stetler-Stevenson, M., Yuan, C. M., et al. (2018) · Blood · doi:10.1182/blood-2017-12-820910 · Cited by 205
Chang, B. Y., Francesco, M., De Rooij, M. F. M., Magadala, P., Steggerda, S. M., Huang, M. M., Kuil, A., Herman, S. E. M., Chang, S., Pals, S. T., et al. (2013) · Blood · doi:10.1182/blood-2013-02-482125 · Cited by 203
Niemann, C. U., Herman, S. E. M., Maric, I., Gomez-Rodriguez, J., Biancotto, A., Chang, B. Y., Martyr, S., Stetler-Stevenson, M., Yuan, C. M., Calvo, K. R., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1965 · Cited by 201
Younes, A., Brody, J., Carpio, C., Lopez-Guillermo, A., Ben-Yehuda, D., Ferhanoglu, B., Nagler, A., Ozcan, M., Avivi, I., Bosch, F., et al. (2019) · The Lancet Haematology · doi:10.1016/s2352-3026(18)30217-5 · Cited by 194
Mahajan, S., Ghosh, S., Sudbeck, E. A., Zheng, Y., Downs, S., Hupke, M., & Uckun, F. M. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.14.9587 · Cited by 191
Awan, F. T., Schuh, A., Brown, J. R., Furman, R. R., Pagel, J. M., Hillmen, P., Stephens, D. M., Woyach, J., Bibikova, E., Charuworn, P., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018030007 · Cited by 185
Song, Y., Zhou, K., Zou, D., Zhou, J., Hu, J., Yang, H., Zhang, H., Ji, J., Xu, W., Jin, J., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3703 · Cited by 184
Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia
Treon, S. P., Gustine, J., Meid, K., Yang, G., Xu, L., Liu, X., Demos, M., Kofides, A., Tsakmaklis, N., Chen, J. G., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.6426 · Cited by 182
Treatment recommendations from the Eighth International Workshop on Waldenström’s Macroglobulinemia
Leblond, V., Kastritis, E., Advani, R., Ansell, S. M., Buske, C., Castillo, J. J., García-Sanz, R., Gertz, M., Kimby, E., Kyriakou, C., et al. (2016) · Blood · doi:10.1182/blood-2016-04-711234 · Cited by 181
Byrd, J. C., Wierda, W. G., Schuh, A., Devereux, S., Chaves, J. M., Brown, J. R., Hillmen, P., Martin, P., Awan, F. T., Stephens, D. M., et al. (2020) · Blood · doi:10.1182/blood.2018884940 · Cited by 178
Owen, R. G., McCarthy, H., Rule, S., D'Sa, S., Thomas, S. K., Tournilhac, O., Forconi, F., Kersten, M. J., Zinzani, P. L., Iyengar, S., et al. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(19)30210-8 · Cited by 167
Tai, Y.-T., Chang, B. Y., Kong, S.-Y., Fulciniti, M., Yang, G., Calle, Y., Hu, Y., Lin, J., Zhao, J.-J., Cagnetta, A., et al. (2012) · Blood · doi:10.1182/blood-2011-12-396853 · Cited by 165
Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial
Bartlett, N. L., Costello, B. A., LaPlant, B. R., Ansell, S. M., Kuruvilla, J. G., Reeder, C. B., Thye, L. S., Anderson, D. M., Krysiak, K., Ramirez, C. A., et al. (2017) · Blood · doi:10.1182/blood-2017-09-804641 · Cited by 165
Rule, S. A., Dreyling, M. H., Goy, A. H., Heß, G., Auer, R. L., Kahl, B. S., Cavazos, N., Liu, B., Yang, S., Clow, F., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.14870 · Cited by 160
Jerkeman, M., Eskelund, C. W., Hutchings, M., Räty, R., Wader, K. F., Laurell, A., Toldbod, H., Pedersen, L. B., Niemann, C. U., Dahl, C., et al. (2018) · The Lancet Haematology · doi:10.1016/s2352-3026(18)30018-8 · Cited by 154
Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia
Xu, L., Tsakmaklis, N., Yang, G., Chen, J. G., Liu, X., Demos, M. G., Kofides, A., Patterson, C. J., Meid, K., Gustine, J. N., et al. (2017) · Blood · doi:10.1182/blood-2017-01-761726 · Cited by 152
Syed, Y. Y. (2020) · Drugs · doi:10.1007/s40265-019-01252-4 · Cited by 150
Jaglowski, S. M., Jones, J. A., Nagar, V., Flynn, J. M., Andritsos, L. A., Maddocks, K. J., Woyach, J. A., Blum, K. A., Grever, M. R., Smucker, K. A., et al. (2015) · Blood · doi:10.1182/blood-2014-12-617522 · Cited by 142
Goy, A. H., Ramchandren, R., Ghosh, N., Munoz, J. L., Morgan, D., Dang, N. H., Knapp, M. H., Delioukina, M. L., Kingsley, E. C., Ping, J., et al. (2019) · Blood · doi:10.1182/blood.2018891598 · Cited by 137
Coutre, S. E., Byrd, J. C., Hillmen, P., Barrientos, J. C., Barr, P. M., Devereux, S., Robak, T., Kipps, T. J., Schuh, A., Moreno, C., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018028761 · Cited by 134
Maddocks, K. J., Christian, B. A., Jaglowski, S. M., Flynn, J. M., Jones, J. A., Porcu, P., Wei, L., Jenkins, C., Lozanski, G., Byrd, J. C., et al. (2014) · Blood · doi:10.1182/blood-2014-08-597914 · Cited by 133
Fraser, G. A. M., Cramer, P., Demırkan, F., da Silva, R. S. A., Grosicki, S., Pristupa, A. S., Janssens, A. M., Mayer, J., Bartlett, N. L., Dilhuydy, M. S., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0276-9 · Cited by 119
Brown, J. R., Barrientos, J. C., Barr, P. M., Flinn, I. W., Burger, J. A., Tran, A., Clow, F., James, D. F., Graef, T. T., Friedberg, J. W., et al. (2015) · Blood · doi:10.1182/blood-2014-09-585869 · Cited by 118
Gopal, A. K., Schuster, S. J., Fowler, N. H., Trotman, J., Heß, G., Hou, J., Yacoub, A., Lill, M., Martin, P., Vitolo, U., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.8853 · Cited by 105
Sun, C., Nierman, P., Kendall, E. K., Cheung, J., Gulrajani, M., Herman, S. E. M., Pleyer, C., Ahn, I. E., Stetler-Stevenson, M., Yuan, C. M., et al. (2020) · Blood · doi:10.1182/blood.2019003715 · Cited by 103
Rule, S. A., Jurczak, W. J., Jerkeman, M., Rusconi, C., Trněný, M., Offner, F. C., Caballero, D. M., Joao, C. M., Witzens‐Harig, M., Hess, G., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0023-2 · Cited by 103
Overman, M. J., Javle, M. M., Davis, R. E., Vats, P., Kumar‐Sinha, C., Xiao, L., Mettu, N. B., Parra, E. R., Benson, A. B., Lopez, C. D., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000587 · Cited by 101
Zhao, X., Bodo, J., Sun, D., Durkin, L. M., Lin, J. J., Smith, M. R., & Hsi, E. D. (2014) · British Journal of Haematology · doi:10.1111/bjh.13149 · Cited by 100
Li, N., Huang, H., Wu, D., Yang, Z., Wang, J., Wang, J., Wang, S., Fang, H., Yu, Y., Bai, Y., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30491-7 · Cited by 93
Self-citationAbrams, S. T., Lakum, T., Lin, K., Jones, G. M., Treweeke, A. T., Farahani, M., Hughes, M. E., Zuzel, M., & Slupsky, J. R. (2006) · Blood · doi:10.1182/blood-2006-03-012021 · Cited by 88
Dasmahapatra, G. P., Patel, H. J., Dent, P., Fisher, R. I., Friedberg, J. W., & Grant, S. (2013) · British Journal of Haematology · doi:10.1111/bjh.12206 · Cited by 88
A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma
Martin, P., Bartlett, N. L., Blum, K. A., Park, S. I., Maddocks, K. J., Ruan, J., Ridling, L., Dittus, C. E., Chen, Z., Huang, X., et al. (2019) · Blood · doi:10.1182/blood-2018-11-886457 · Cited by 84
Hong, D. S., Rasco, D. W., Veeder, M. H., Luke, J. J., Chandler, J. C., Balmanoukian, A. S., George, T. J., Münster, P. N., Berlin, J. D., Gutierrez, M. E., et al. (2019) · Oncology · doi:10.1159/000500571 · Cited by 83
Woyach, J. A., Blachly, J. S., Rogers, K. A., Bhat, S. A., Jianfar, M., Lozanski, G., Weiss, D. M., Andersen, B. L., Gulrajani, M., Frigault, M. M., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1130 · Cited by 83
Davids, M. S., Brander, D. M., Kim, H. T., Tyekucheva, S., Bsat, J., Savell, A., Hellman, J. M., Bazemore, J., Francoeur, K., Alencar, A. J., et al. (2019) · The Lancet Haematology · doi:10.1016/s2352-3026(19)30104-8 · Cited by 74
Kil, L. P., de Bruijn, M. J. W., van Hulst, J. A. C., Langerak, A. W., Yuvaraj, S., & Hendriks, R. W. (2013) · Europe PMC (PubMed Central) · Cited by 72
Harrington, B. K., Gardner, H. L., Izumi, R. E., Hamdy, A., Rothbaum, W. M., Coombes, K. R., Covey, T. M., Kaptein, A., Gulrajani, M., van Lith, B., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0159607 · Cited by 65
Jain, P., Romaguera, J. E., Srour, S. A., Lee, H. J., Hagemeister, F. B., Westin, J. R., Fayad, L., Samaniego, F., Badillo, M., Zhang, L., et al. (2018) · British Journal of Haematology · doi:10.1111/bjh.15411 · Cited by 64
Coutre, S. E., Furman, R. R., Flinn, I. W., Burger, J. A., Blum, K. A., Sharman, J. P., Jones, J. A., Wierda, W. G., Zhao, W., Heerema, N. A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1431 · Cited by 62
Ujjani, C. S., Jung, S., Pitcher, B. N., Martin, P., Park, S. I., Blum, K. A., Smith, S. M., Czuczman, M. S., Davids, M. S., Levine, E. G., et al. (2016) · Blood · doi:10.1182/blood-2016-06-718106 · Cited by 60
Jain, P., Keating, M. J., Wierda, W. G., Sivina, M., Thompson, P. A., Ferrajoli, A., Estrov, Z. E., Kantarjian, H. M., O'Brien, S. M., & Burger, J. A. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1948 · Cited by 57
Zou, Y., Zhu, H., Li, X., Xia, Y., Miao, K., Zhao, S., Wu, Y., Wang, L., Xu, W., & Li, J. (2019) · Hematological Oncology · doi:10.1002/hon.2667 · Cited by 57
Flinsenberg, T. W. H., Tromedjo, C. C., Hu, N., Liu, Y., Guo, Y., Thia, K. Y. T., Noori, T., Song, X., Aw Yeang, H. X., Tantalo, D. G., et al. (2020) · Haematologica · doi:10.3324/haematol.2019.220590 · Cited by 56
Axelrod, M. J., Ou, Z., Brett, L. K., Zhang, L., Lopez, E., Tamayo, A., Gordon, V. L., Ford, R. J., Williams, M. E., Pham, L. V., et al. (2013) · Leukemia · doi:10.1038/leu.2013.249 · Cited by 48
Targeting Bruton’s Tyrosine Kinase Across B-Cell Malignancies
da Cunha‐Bang, C., & Niemann, C. U. (2018) · Drugs · doi:10.1007/s40265-018-1003-6 · Cited by 48
Bartlett, N. L., LaPlant, B. R., Qi, J., Ansell, S. M., Kuruvilla, J. G., Reeder, C. B., Thye, L. S., Anderson, D. M., Erlichman, C., & Siegel, B. A. (2014) · Blood · doi:10.1182/blood.v124.21.800.800 · Cited by 39
Richardson, P. G. G., Bensinger, W., Huff, C. A., Costello, C. L., Lendvai, N. K., Berdeja, J. G., Anderson, L. D., Siegel, D. S. D., Lebovic, D. J., Jagannath, S., et al. (2018) · British Journal of Haematology · doi:10.1111/bjh.15058 · Cited by 38
Alsadhan, A., Cheung, J. P., Gulrajani, M., Gaglione, E. M., Nierman, P., Hamdy, A., Izumi, R. E., Бибикова, Е., Patel, P. S., Sun, C., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3505 · Cited by 35
Tam, C. S. L., Wang, M., Simpson, D., Opat, S., Cull, G., Munoz, J. L., Phillips, T. J., Kim, W., Atwal, S. K., Wei, R., et al. (2019) · Hematological Oncology · doi:10.1002/hon.55_2630 · Cited by 29
Chari, A., Larson, S. M., Holkova, B., Cornell, R. F., Gasparetto, C., Karanes, C., Matous, J., Niesvizky, R., Valent, J. N., Lunning, M. A., et al. (2018) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2018.1443337 · Cited by 25
Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia
O'Brien, S. M., Jaglowski, S. M., Byrd, J. C., Bannerji, R., Blum, K. A., Fox, C. P., Furman, R. R., Hillmen, P., Kipps, T. J., Montillo, M., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.5604 · Cited by 22
Wang, M. L., Jain, P., Lee, H. J., Hagemeister, F. B., Samaniego, F., Westin, J. R., Nastoupil, L. J., Chen, W., Nomie, K. J., Zhang, S., et al. (2019) · Blood · doi:10.1182/blood-2019-126044 · Cited by 15
Jain, P., Lee, H. J., Steiner, R. E., et al. (2019) · Blood · doi:10.1182/blood-2019-125800 · Cited by 12
Cited by
Byrd, J. C., Hillmen, P., Ghia, P., Kater, A. P., Chanan-Khan, A., Furman, R. R., O'Brien, S., Yenerel, M. N., Illés, A., Kay, N., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01210 · Cited by 669
Rheumatoid Arthritis: Pathogenic Roles of Diverse Immune Cells
Jang, S., Kwon, E.-J., & Lee, J. J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020905 · Cited by 612
Molecular targeted therapy for anticancer treatment
Min, H.-Y., & Lee, H.-Y. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00864-3 · Cited by 569
Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures
Hallek, M., & Al‐Sawaf, O. (2021) · American Journal of Hematology · doi:10.1002/ajh.26367 · Cited by 393
Radiopharmaceuticals for PET and SPECT Imaging: A Literature Review over the Last Decade
Crișan, G., Moldovean-Cioroianu, N. S., Timaru, D.-G., Andrieș, G., Căinap, C., & Chiș, V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23095023 · Cited by 337
Metadata
- Authors
- Wen, T., Wang, J., Shi, Y., Qian, H., & Liu, P.
- Venue
- Leukemia
- Published
- 2020-10-29
- Volume
- 35
- Issue
- 2
- Pages
- 312-332
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W3094893995
- Cited by
- 262
- References
- 115
- FWCI
- 17.05
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.